| NCT00787202 |
A Study To Investigate The Safety And Efficacy Of CP- 690,550 In Patients With Moderate And Severe Ulcerative Colitis. |
PHASE2 |
COMPLETED |
Pfizer |
Ulcerative Colitis |
DRUG: CP- 690 550|DRUG: CP- 690 550|DRUG: CP- 690… |
Details |
| NCT06321887 |
EffiCacy and sAfEty of Low doSe orAl iRon for Anaemia in IBD |
PHASE3 |
RECRUITING |
Liverpool University Hospitals NHS Foundation Trust |
Inflammatory Bowel Disease|Iron Deficiency Anemia |
DRUG: Ferrous fumarate syrup 2.5ml/70mg (22.5mg e… |
Details |
| NCT02762500 |
An Efficacy and Safety Study of LYC-30937-EC in Subjects With Active Ulcerative Colitis |
PHASE2 |
COMPLETED |
Lycera Corp. |
Colitis, Ulcerative |
DRUG: LYC-30937-EC|DRUG: Placebo |
Details |
| NCT03943550 |
Double-Blinded, Placebo-Controlled Phase 1b Study for Safety, PK, Efficacy, PD of RO7049665 in Participants With Ulcerative Colitis (UC) |
PHASE1 |
TERMINATED |
Hoffmann-La Roche |
Ulcerative Colitis |
DRUG: RO7049665|DRUG: Placebo |
Details |
| NCT02392221 |
Impact of Therapeutic Strategies in the Pediatric Inflammatory Bowel Disease: a Population Based Study (1988-2011). |
None |
COMPLETED |
Centre Hospitalier Universitaire, Amiens |
Pediatric Inflammatory Bowel Disease |
None |
Details |
| NCT01465763 |
A Study Evaluating The Efficacy And Safety Of CP-690,550 In Patients With Moderate To Severe Ulcerative Colitis |
PHASE3 |
COMPLETED |
Pfizer |
Ulcerative Colitis |
DRUG: tofacitinib|DRUG: Placebo |
Details |
| NCT01100112 |
(CB-01-02/06) Oral Budesonide-Multi-Matrix System (MMX) 9mg Extended Release Tablets |
PHASE3 |
COMPLETED |
Bausch Health Americas, Inc. |
Colitis, Ulcerative |
DRUG: Budesonide |
Details |
| NCT06636656 |
A Study to Test Whether BI 3032950 Helps People With Ulcerative Colitis |
PHASE2 |
RECRUITING |
Boehringer Ingelheim |
Ulcerative Colitis |
DRUG: BI 3032950 intravenous (Part A)|DRUG: BI 30… |
Details |
| NCT01458951 |
A Study To Evaluate Both The Efficacy and Safety Profile of CP-690,550 In Patients With Moderately to Severely Active Ulcerative Colitis |
PHASE3 |
COMPLETED |
Pfizer |
Ulcerative Colitis |
DRUG: tofacitinib|DRUG: Placebo |
Details |
| NCT02318667 |
Correlation of Soluble Suppression of Tumorigenicity 2 (ST2) With Golimumab (MK-8259) Response in Participants With Ulcerative Colitis (UC) (MK-8529-022). |
PHASE4 |
COMPLETED |
Merck Sharp & Dohme LLC |
Colitis, Ulcerative |
BIOLOGICAL: Golimumab |
Details |
| NCT01470612 |
Long-Term Study Of CP-690,550 In Subjects With Ulcerative Colitis |
PHASE3 |
COMPLETED |
Pfizer |
Ulcerative Colitis |
DRUG: CP-690,550|DRUG: CP-690,550 |
Details |
| NCT02493712 |
A Phase 2a, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Trial of IBD98-M |
PHASE2 |
COMPLETED |
Holy Stone Healthcare Co., Ltd |
Colitis, Ulcerative |
DRUG: High dose|DRUG: Low dose|DRUG: Placebo |
Details |
| NCT06786507 |
A Direct Head-to-head Comparison of Ustekinumab with Infliximab for the Treatment of Ulcerative Colitis |
None |
NOT_YET_RECRUITING |
Helwan University |
Ulcerative Colitis (UC) |
DRUG: Ustekinumab 90 mg|DRUG: Infliximab |
Details |
| NCT06260267 |
A Phase 1b Proof-of-concept Trial Exploring the Effects of FE 999322 and FE 999324 in Adults With Mild to Moderate Ulcerative Colitis |
PHASE1 |
WITHDRAWN |
Ferring Pharmaceuticals |
Ulcerative Colitis |
DRUG: Microbiota suspension|DRUG: Microbiota caps… |
Details |
| NCT02246686 |
Efficacy/Safety Pilot Study to Investigate Iberogast N's Efficacy in Mild to Moderate Colitis Ulcerosa Patients |
PHASE2 |
TERMINATED |
Bayer |
Colitis, Ulcerative |
DRUG: STW5-II (Iberogast N, BAY98-7410)|DRUG: Pla… |
Details |
| NCT04969679 |
Additive Effect of Probiotics (Mutaflor) in Patients With Ulcerative Colitis on 5-ASA Treatment. |
PHASE4 |
COMPLETED |
Kangbuk Samsung Hospital |
Ulcerative Colitis |
DRUG: E. coli Nissle 1917 (Mutaflor)|DRUG: Placebo |
Details |
| NCT00355901 |
An Observational Follow-up Study for Subjects Receiving Salvage Therapy After Previous Treatment in a Visilizumab Study for Intravenous Steroid-Refractory Ulcerative Colitis |
None |
TERMINATED |
PDL BioPharma, Inc. |
Ulcerative Colitis |
DRUG: Visilizumab (Nuvion; HuM291) |
Details |
| NCT01036022 |
Effect of GSK1399686 in Patients With Mild to Moderately Active Ulcerative Colitis |
PHASE2 |
COMPLETED |
GlaxoSmithKline |
Colitis, Ulcerative |
DRUG: GSK1399686 |
Details |
| NCT04411784 |
PROTECT-ASUC: Covid-19 Pandemic Response Of assessmenT, EndosCopy and Treatment in Acute Severe Ulcerative Colitis |
None |
COMPLETED |
Hull University Teaching Hospitals NHS Trust |
Inflammatory Bowel Diseases|COVID |
None |
Details |
| NCT01320332 |
A Study of a Single Dose of ASP3291 in Subjects With Ulcerative Colitis |
PHASE1 |
COMPLETED |
Telsar Pharma Inc. |
Ulcerative Colitis |
DRUG: ASP3291|DRUG: Placebo |
Details |
